RFRP Inhibitors
RFamide-related peptide (RFRP) inhibitors are chemical compounds that specifically target and inhibit the activity of RFRP neurons, which are part of the broader RFamide neuropeptide family. RFRPs, particularly RFRP-3, are structurally characterized by the presence of a conserved C-terminal arginine (R) and phenylalanine (F) sequence, which gives the family its name. These peptides are involved in the modulation of neuroendocrine functions, especially influencing the hypothalamic-pituitary-gonadal (HPG) axis and related neuroendocrine processes. The inhibition of RFRP signaling occurs through specific antagonistic interactions with RFRP receptors, such as GPR147, which mediate the biological actions of these peptides. By inhibiting RFRP activity, RFRP inhibitors play a role in altering neuroendocrine feedback loops, which has been an area of interest for research into neuropeptide regulatory mechanisms.
In terms of their chemical properties, RFRP inhibitors are often small molecules or peptides that mimic or disrupt the binding interactions between RFRPs and their receptors. These inhibitors can be designed with high specificity for the GPR147 receptor, ensuring selective modulation of RFRP signaling without affecting other RFamide-related pathways. Structural studies have contributed to understanding the binding dynamics between RFRPs and their receptors, aiding in the development of more potent and selective inhibitors. The specificity of these inhibitors is crucial for dissecting the complex signaling mechanisms in neuroendocrine systems, where multiple neuropeptides often act in overlapping or complementary ways. Through this lens, RFRP inhibitors are valuable tools for probing the precise role of RFRP neuropeptides in various physiological processes, allowing scientists to explore how these peptides interact with broader neurochemical and hormonal networks.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, as an HDAC inhibitor, could lead to hyperacetylation of histones, thereby potentially causing the chromatin around the RFRP gene to become less accessible for transcription factors, which would likely result in a decrease of RFRP expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine may lead to the hypomethylation of DNA within the promoter region of the RFRP gene, which can silence genes that are typically active; however, if RFRP expression is normally suppressed by methylation, decitabine could inadvertently reduce its expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A, by binding to specific DNA sequences, may directly obstruct the binding of transcription factors necessary for the initiation of RFRP transcription, leading to a downregulation of the RFRP gene. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and blocks the elongation phase of RNA synthesis by inhibiting RNA polymerase. This blockade could lead to a broad suppression of gene expression, including a decrease in RFRP mRNA synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin directly binds to mTOR and inhibits its activity, which could lead to a reduction in cellular processes that are mTOR-dependent, potentially including the synthesis of molecules that promote RFRP expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 inhibits PI3K with a consequent reduction in AKT signaling. The downstream effect of this inhibition could lead to a decrease in factors that are responsible for the transcriptional initiation of the RFRP gene. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, through its binding to nuclear hormone receptors, can repress or activate gene transcription. This compound could potentially repress transcription factors or coactivators necessary for RFRP gene expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been documented to downregulate the expression of certain genes by inhibiting nuclear factor-kappa B (NF-κB) activation. This action could extend to a reduction in RFRP expression if NF-κB is involved in its transcriptional activation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol has been reported to downregulate the expression of genes involved in inflammatory responses, possibly through inhibition of NF-κB. A similar mechanism might result in the downregulation of RFRP expression. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can bind to copper ions, forming a complex that inhibits proteasomes. This could lead to an accumulation of ubiquitinated proteins, possibly altering the ubiquitin-proteasome pathway and reducing RFRP expression. | ||||||